This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy alone in treating…
- Investigator
- Daniel V Araujo
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All